(IN BRIEF) Sanofi has reported that Nexviazyme met its primary and all secondary endpoints in the Baby-COMET Phase 3 study in treatment-naïve infants with infantile-onset Pompe disease. The primary endpoint assessed the proportion of participants aged six months or younger … Read the full press release
